US 12,338,287 B2
Treatment of cancer using a CD33 chimeric antigen receptor
Hilmar Erhard Ebersbach, Basel (CH); Thomas Huber, Basel (CH); Julia Jascur, Basel (CH); Celeste Richardson, Cambridge, MA (US); Reshma Singh, Cambridge, MA (US); Huijuan Song, Shanghai (CN); Qilong Wu, Shanghai (CN); and Jiquan Zhang, Shanghai (CN)
Assigned to Novartis AG, Basel (CH); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by Novartis AG, Basel (CH); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed on Oct. 28, 2020, as Appl. No. 17/083,211.
Application 17/083,211 is a division of application No. 15/689,163, filed on Aug. 29, 2017, granted, now 10,851,166.
Application 15/689,163 is a division of application No. 14/805,236, filed on Jul. 21, 2015, granted, now 9,777,061, issued on Oct. 3, 2017.
Claims priority of application No. PCT/CN2014/082589 (WO), filed on Jul. 21, 2014; and application No. PCT/CN2014/090504 (WO), filed on Nov. 6, 2014.
Prior Publication US 2021/0139595 A1, May 13, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 31/436 (2006.01); A61K 31/711 (2006.01); A61K 35/28 (2015.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/2851 (2013.01) [A61K 31/436 (2013.01); A61K 31/711 (2013.01); A61K 35/28 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 39/39558 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/421 (2025.01); A61K 40/4217 (2025.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/7056 (2013.01); C07K 14/70578 (2013.01); C07K 14/7151 (2013.01); C07K 16/2803 (2013.01); C07K 16/30 (2013.01); C07K 16/3061 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A method of inducing an immune response in a mammal, comprising administering to the mammal an effective amount of a population of immune effector cells comprising a chimeric antigen receptor (CAR) polypeptide, wherein the CAR polypeptide comprises a CD33 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the intracellular domain comprises a costimulatory domain, a primary signaling domain, or both a costimulatory domain and a primary signaling domain, and wherein said CD33 binding domain comprises a heavy chain variable region and a light chain variable region selected from the group consisting of:
(i) a heavy chain variable region comprising:
a heavy chain complementary determining region 1 (HC CDR1) comprising the sequence of SEQ ID NO: 274, a heavy chain complementary determining region 2 (HC CDR2) comprising the sequence of SEQ ID NO: 283, and a heavy chain complementary determining region 3 (HC CDR3) comprising the sequence of SEQ ID NO:292 present in order of HC CDR1, HC CDR2, and HC CDR3; and
a light chain variable region comprising:
a light chain complementarity determining region 1 (LC CDR1) comprising the sequence of SEQ ID NO: 301, a light chain complementarity determining region 2 (LC CDR2) comprising the sequence of SEQ ID NO: 310, and a light chain complementarity determining region 3 (LC CDR3) comprising the sequence of SEQ ID NO:319 present in order of LC CDR1, LC CDR2, and LC CDR3;
(ii) a heavy chain variable region comprising:
a heavy chain complementarity determining region 1 (HC CDR1) comprising the sequence of SEQ ID NO: 328, a heavy chain complementarity determining region 2 (HC CDR2) comprising the sequence of SEQ ID NO: 337, and a heavy chain complementarity determining region 3 (HC CDR3) comprising the sequence of SEQ ID NO:346 present in order of HC CDR1, HC CDR2, and HC CDR3; and
a light chain variable region comprising:
a light chain complementarity determining region 1 (LC CDR1) comprising the sequence of SEQ ID NO: 355, a light chain complementarity determining region 2 (LC CDR2) comprising the sequence of SEQ ID NO: 364, and a light chain complementarity determining region 3 (LC CDR3) comprising the sequence of SEQ ID NO:373 present in order of LC CDR1, LC CDR2, and LC CDR3; and
(iii) a heavy chain variable region comprising:
a heavy chain complementarity determining region 1 (HC CDR1) comprising the sequence of SEQ ID NO: 89, a heavy chain complementarity determining region 2 (HC CDR2) comprising the sequence of SEQ ID NO: 98, and a heavy chain complementarity determining region 3 (HC CDR3) comprising the sequence of SEQ ID NO: 107, present in order of HC CDR1, HC CDR2, and HC CDR3; and
a light chain variable region comprising:
a light chain complementarity determining region 1 (LC CDR1) comprising the sequence of SEQ ID NO: 116, a light chain complementarity determining region 2 (LC CDR2) comprising the sequence of SEQ ID NO: 125, and a light chain complementarity determining region 3 (LC CDR3) comprising the sequence of SEQ ID NO: 134 present in order of LC CDR1, LC CDR2, and LC CDR3.